首页> 外文期刊>Biochemical Pharmacology >Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients
【24h】

Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients

机译:细胞色素P450 2D6和3A5基因型及可能的联合用药对日本患者抗抑郁药米氮平的代谢清除率的影响

获取原文
获取原文并翻译 | 示例
           

摘要

A personalized treatment approach should be considered with the second-generation psychiatric drug mirtazapine because of high frequencies of side effects, including characteristic drowsiness. Plasma concentrations of mirtazapine in patients are influenced by many factors, including polymorphic cytochrome P450 enzymes contributing to its transformation to 8-hydroxymirtazapine and N-demethylmirtazapine. The aim of this study was to investigate the determinant factors for individual variations of metabolic clearance of mirtazapine using in vitro and in vivo methods. In vitro analyses using liver microsomes from individual humans in correlation assays and recombinantly expressed P450 enzymes revealed that CYP2D6 was the major contributor to mirtazapine 8-hydroxylation with high affinity, and that CYP3A5 catalyzed N-demethylation in a similar high-capacity manner to that of CYP3A4. CYP1A2 was a minor contributor to mirtazapine 8-hydroxylation. Metabolic clearance of mirtazapine determined in substrate depletion assays and mirtazapine 8-hydroxylation activities in individual liver microsomes were significantly lower in CYP2D6 intermediate metabolizers (IM) and poor metabolizers (PM) than in extensive metabolizers (EM) (p < 0.05). Trough plasma concentration/dose ratios of mirtazapine from 14 patients were significantly higher in the CYP2D6 IM/PM group than in the EM group and were also higher in the CYP3A5 poor-expressors group than in the expressors group (p < 0.05). Mirtazapine clearance in pooled human liver microsomes was inhibited by quinidine (a CYP2D6 inhibitor), ketoconazole (a CYP3A inhibitor), and in combination with risperidone and duloxetine, possible coadministered medicines. These results suggested that mirtazapine metabolic clearance could be variously influenced by the CYP2D6 and CYP3A5 genotypes and coadministered drugs in clinical patients. (C) 2014 Elsevier Inc. All rights reserved.
机译:第二代精神药物米氮平应考虑采用个性化治疗方法,因为副作用频发,包括嗜睡。患者中米氮平的血浆浓度受多种因素影响,包括多态性细胞色素P450酶有助于其转化为8-羟基米氮平和N-去甲基米氮平。这项研究的目的是使用体外和体内方法研究米氮平代谢清除率的个体变化的决定因素。在相关试验中使用来自各个人的肝微粒体和重组表达的P450酶进行的体外分析显示,CYP2D6是米氮平8-羟基化反应的主要促成因素,具有高亲和力,并且CYP3A5催化的N-去甲基化的能力类似于CYP3A4。 CYP1A2对mirtazapine 8-hydroxylation的贡献较小。在底物耗竭试验中确定的米氮平的代谢清除率和个别肝脏微粒体中的米氮平8-羟基化活性在CYP2D6中间代谢物(IM)和弱代谢物(PM)中显着低于广泛代谢物(EM)(p <0.05)。 CYP2D6 IM / PM组的14名患者的米氮平的谷血浆浓度/剂量比显着高于EM组,并且CYP3A5弱表达组也高于表达组(p <0.05)。奎尼丁(一种CYP2D6抑制剂),酮康唑(一种CYP3A抑制剂)以及与利培酮和度洛西汀联用可能抑制联合用药,抑制合并的人肝微粒体中的米氮平清除率。这些结果表明,在临床患者中,米氮平的代谢清除率可能受到CYP2D6和CYP3A5基因型以及共同给药药物的影响。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号